Dine Brands Global, Inc. (NYSE: DIN), the parent company of Applebee’s Neighborhood Grill & Bar® and IHOP® restaurants, today announced that Vance Chang has been named Chief Financial Officer, effective June 14, 2021.
Top companies covered are Bayer CropScience (Leverkusen, Germany), alagro S.p.A (Atessa, Italy), BASF SE (Ludwigshafen, Germany), Isagro S.p.A (Milan, Italy), Syngenta AG (Basel, Switzerland), UPL (Mumbai, India), Biostadt India Limited (Mumbai, India), Koppert Biological Systems (Rodenrijs, Netherlands), Biochimica S.p.A (Bologna, Italy), Lallemand (Wisconsin, United States), Marrone Bio Innovations (California, United States), AlgaEnergy (Madrid, Spain), and more players profiled in biostimulants market research reportPune, India, May 12, 2021 (GLOBE NEWSWIRE) -- The global biostimulants market size is expected to gain traction by reaching USD 5.35 billion by 2027. This information is published by Fortune Business Insights in its report, titled “Biostimulants Market, 2020 – 2027.” The report further mentions that the market stood at USD 2.50 billion in 2019 and is projected to exhibit a CAGR of 10.65% between 2020 and 2027. The increasing demand for organic food products and the increasing support from the government to promote bio-agri products will boost the adoption of the product worldwide. For instance, in February 2021, the Government of India allocated around INR 126 crore for the Startup India Seed Fund for the fiscal year 2021-22. According to the government, the funds are meant to provide able assistance financially to the startups involved in sectors such as biotechnology, water management, and others. COVID-19 has resulted in several economies facing unprecedented loss. Owing to the lockdown announced by the government agencies globally, several manufacturing facilities have been at a standstill with limited operational activities. However, a collective effort from the government and the industries to bring the economy back is expected to boost the market growth during the forecast period. Market Segmentation Based on source, the market is bifurcated into microbial and non-microbial. On the basis of active ingredients, the market is classified into seaweed extracts, humic substances, vitamins & amino acids, microbial amendments, and others. Moreover, based on application, the market is segregated into foliar application, soil treatment, and seed treatment. Besides, on the basis of crop, the market is classified into row crops, fruits & vegetables, turf & ornamentals, and others. Based on crop, the row crops segment held a global biostimulants market share of about 45.78% in 2019 and is expected to showcase considerable growth in the forthcoming years. This is due to the large cultivation area. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biostimulants-market-100414 What does the Report Include? The global market for biostimulants report includes qualitative and quantitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers different regions, which are contributing to the growth of the market. It includes the competitive landscape that involves the leading companies and the adoption of strategies by them to announce partnerships, introduce new products, and collaboration that will further contribute to the growth of the market between 2020 and 2027. Moreover, the research analyst has adopted several research methodologies such as SWOT and PESTEL analysis to extract information about the current trends and industry developments that will drive the market growth during the forecast period. DRIVING FACTORS Increasing Demand for Organic Food Products to Propel Market Growth According to the Pesticide Action Network UK, prolonged exposure to synthetic pesticides has been linked to the onset of chronic disorders such as cancer, asthma, Parkinson’s, anxiety, etc. Besides, these types of pesticides contaminate water, soil, vegetation, and air while having an adverse effect on human beings upon consumption. Therefore, the increasing awareness regarding the ill-effect of these products has led to the adoption of organic products in the agriculture sector. The microbial and plant-derived products aid in enhancing the growth of the plant, improving fertility, and have negligible impact on the environment. Owing to these factors, the surging consumption of organic produce is anticipated to contribute to the global biostimulants market growth during the foreseeable future. List of the Companies Profiled in the Biostimulants Market are: Bayer CropScience (Leverkusen, Germany)Valagro S.p.A (Atessa, Italy)BASF SE (Ludwigshafen, Germany)Isagro S.p.A (Milan, Italy)Syngenta AG (Basel, Switzerland)UPL (Mumbai, India)Biostadt India Limited (Mumbai, India)Koppert Biological Systems (Rodenrijs, Netherlands)Biochimica S.p.A (Bologna, Italy)Lallemand (Wisconsin, United States)Marrone Bio Innovations (California, United States)AlgaEnergy (Madrid, Spain) Browse Detailed Summary of Research Report with TOC: https://www.fortunebusinessinsights.com/industry-reports/biostimulants-market-100414 REGIONAL INSIGHTS North America – The region stood at USD 582.23 million in 2019 and is expected to hold a significant position in the market during the forecast period. This is attributable to the growing adoption of advanced technology in agriculture and the supportive government policies that promote the utilization of sustainable farming practices in the region. Asia-Pacific – The market in the region is expected to experience significant growth backed by the increasing adoption of quality agriculture products and the surging organic farming sector that will propel the demand for advanced biostimulants in the region between 2020 and 2027. COMPETITIVE LANDSCAPE Major Companies Invest in R&D Activities to Strengthen Their Market Positions The market is fragmented by major companies that are focusing on maintaining their presence. They are doing so by proactively investing in the R&D activities to develop advanced biostimulants to cater to the growing demand for organic techniques in the agriculture sector. Additionally, other key players are adopting organic and inorganic strategies to maintain their position in the global marketplace. Industry Development: March 2020 - Syngenta signed an exclusive 15 years contract with SICIT Group. The contract is aimed at supplying ISABION and HICURE to promote sustainable agriculture. Inquire Before Buying This Research Report: https://www.fortunebusinessinsights.com/enquiry/queries/biostimulants-market-100414 Detailed Table of Content: Introduction Research ScopeMarket SegmentationResearch ApplicationologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket OpportunitiesEmerging Trends Key Insights Overview of the Parent/Related MarketsSeaweed Production & Agriculture UsesBiostimulants Industry SWOT AnalysisSupply Chain & Regulatory AnalysisRecent Industry Developments - Policies, Partnerships, New Product Launches, and Mergers & AcquisitionsQualitative Analysis (in relation to COVID-19) Impact of COVID-19Supply Chain ChallengesPotential Opportunities due to COVID-19 Global Biostimulants Market Analysis, Insights and Forecast, 2016-2027 Key Findings / SummaryMarket Size Estimates and Forecast By Source (Value) Microbial BiostimulantsNon-microbial Biostimulants By Active Ingredients (Value) Seaweed ExtractsHumic SubstancesVitamins & Amino AcidsMicrobial AmendmentsOthers By Application (Value) Foliar TreatmentSoil TreatmentSeed Treatment By Crop (Value) Row CropsFruits & VegetablesTurf & OrnamentalsOthers By Region (Value) North AmericaEuropeAsia PacificSouth AmericaMiddle East & Africa TOC Continued…! Speak to Our Expert: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/biostimulants-market-100414 Have a Look at Related Research Insights: Biofertilizers Market Size, Share & COVID-19 Impact Analysis, By Type (Nitrogen Fixing, Phosphate Solubilizers, and Others), Microorganism (Rhizobium, Azotobacter, Azospirillum, Pseudomonas, Bacillus, VAM, and Others), Application (Seed Treatment, Soil Treatment, and Others), Crop Type, and Regional Forecast, 2020 – 2027 Agricultural Microbials Market Size, Share & COVID-19 Impact Analysis, By Type (Bacteria, Fungi, Virus, and Others), Formulation (Dry and Liquid), Function (Soil Amendment and Crop Protection), Application Method (Foliar Spray, Soil Treatment, Seed Treatment, and Others), Crop (Cereals, Oilseeds & Pulses, Fruits & Vegetables, and Others), and Regional Forecast, 2020 – 2027 Agricultural Biologicals Market Size, Share and Industry Analysis By Type (Biopesticides, Biostimulants, and Biofertilizers), Source (Microbial and Biochemicals), Application Method (Foliar Spray, Soil Treatment, Seed Treatment, and Others), By Crops, and Regional Forecast 2019-2026 About Us: Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: email@example.com LinkedIn: https://www.linkedin.com/company/fortune-business-insights Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd Twitter: https://twitter.com/FBInsightPvtLtd
President Biden is highlighting new efforts to encourage Americans to get COVID-19 shots, including free rides to and from vaccination sites from ride-sharing companies Uber and Lyft, as the pace of shots nationally declines and he looks to meet his July 4 inoculation targets.
Dublin, May 12, 2021 (GLOBE NEWSWIRE) -- The "A Dynamic Threat Landscape Propels the Global Maritime Port Security Market" report has been added to ResearchAndMarkets.com's offering. The study is global, yet split into 7 regions: Africa, Asia-Pacific, Central Asia, Europe, Latin America, the Middle East, and North America. It includes the top 100 ports based on twenty-foot equivalent units (TEUs) handled, corroborated for 196 countries. The shipping industry is responsible for about 90% of global trade by volume. Governments prioritize the safe and secure transportation of goods, including from land to sea at port sites, to ensure economic stability and growth. Ports are regarded as national infrastructure and are both a potential terrorist target and an entry point for terrorists; still, persistent threats (the illegal movement of individuals, weapons, drugs, or other illicit materials) are often higher on the risk register than terrorism-related threats because they are more common and cause greater losses or damage to port operations. Concerns about persistent threats are primarily behind the push to enhance security technology at ports, with the West taking tougher stances on border control to stem the tide of illegal immigration. This research assesses the global maritime port security market through the identification of market trends, drivers and restraints, key technologies, and main developments by region. An examination of notable projects and investments will identify areas of considerable growth and opportunities for security providers. The focus is on the land-side security of a port; the study excludes ship onboard security technologies, automatic identification systems, and vessel traffic services and systems. Technologies include access control and identity management, C2, communication equipment, cybersecurity, data analytics and storage, fire equipment, screening and detection, surveillance, vehicles and platforms, personal protection gear, and managed services. Key Topics Covered: 1. Strategic Imperatives Why Is It Increasingly Difficult to Grow?The Strategic ImperativeThe Impact of the Top Three Strategic Imperatives on the Maritime Port Security MarketGrowth Opportunities Fuel the Growth Pipeline Engine 2. Growth Opportunity Analysis Scope of AnalysisKey FindingsMarket OverviewLegislative OverviewFuture of PortsDigital Transformation across PortsMacro Trend Analysis of the Digital Evolution of PortsMicro Trend Analysis of the Digital Evolution of PortsDrivers and RestraintsGrowth DriversGrowth RestraintsForecast Assumptions and MethodologyGrowth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast by RegionRevenue Forecast AnalysisPort Infrastructure Expansion ProjectsKey CompetitorsCompetitive EnvironmentStrategic Imperatives for Suppliers 3. North America Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 4. Asia-Pacific Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 5. Latin America Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 6. Middle East Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 7. Central Asia Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 8. Europe Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 9. Africa Growth MetricsRevenue ForecastRevenue Forecast by TechnologyRevenue Forecast Analysis 10. Growth Opportunity Universe Growth Opportunity 1: Integrated Systems for Effective Security OperationsGrowth Opportunity 2: Managed Services Business ModelGrowth Opportunity 3: Cyber Security of Physical Security SystemsThe Last Word: 3 Big Predictions 11. Next Steps For more information about this report visit https://www.researchandmarkets.com/r/qmifve CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Gozio Health, an industry-leading, customizable end-to-end mobile platform, and CriticalArc, creators of SafeZone®, the unified safety, security and emergency management solution, today announced a partnership that enables hospitals and health systems to enhance security and safety by adding CriticalArc’s SafeZone to Gozio’s location based services platform.
While this is a wake-up call, it must be noted that it is not just the Coronavirus crisis that can upset our financial plans and stability.
Institutions "failed to protect people" and science-denying leaders eroded public trust in health interventions, the IPPPR said in its long-awaited final report.
The "Hostels Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
The National Bank of Texas has selected Teslar Software's platform to enhance operations and increase transparency within their lending portfolio.
Dave Bautista leads the cast of Zack Snyder’s Army of the Dead releasing on Netflix.
Follow the latest coronavirus updates here
A pet boom in lockdown has fuelled a rise in custody conflict.
MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 7824008. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/. About Akoya BiosciencesAs The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. Investor Contact:David DeuchlerGilmartin Group LLCinvestors@akoyabio.com Media Contact:Michelle LinnBioscribe, Inc.email@example.com
Kopin Corporation (NASDAQ: KOPN), a leading provider of innovative wearable computing technologies and solutions, announced today that Mr. Richard Sneider, Chief Financial Officer, will present at the 16th Annual Needham Virtual Technology & Media Conference on Monday, May 17th at 3:45PM ET.
Downing Strategic Micro-Cap Investment Trust Plc LEI Code: 213800QMYPUW4POFFX69 Net Asset Values The Company announces the following, all of which is unaudited: Total Assets - including current period revenue* at 11 May 2021£46.30mNet Assets - including current period revenue* at 11 May 2021£46.30mNumber of shares in issue (excluding treasury):51,978,201 The Net Asset Value (NAV) per share at 11 May 2021 was: Per Ordinary share (bid price) - including current period revenue*89.08pPer Ordinary share (bid price) - excluding current period revenue*87.86p Ordinary share price 76.00pPremium/(Discount) to NAV (including current period revenue)(14.68%) * Current period revenue covers the period 01/03/2020 to 11/05/2021 and includes undistributed revenue in respect of that period.
Lakeview Community Partners Limited (LCPL), the developers behind Lakeview Village, a vibrant 177-acre mixed-use community coming to Mississauga's waterfront, today announced the launch of its exciting next phase of collaboration with Artscape to commission a new series of public art set to animate the development site and its future Discovery Centre in 2021 and beyond. This latest initiative will create over $250,000 in paid work opportunities for artists in the region.
MassRoots, Inc. ("MassRoots" or the "Company") (OTCPink:MSRT) today issued the following update on its planned acquisition of Empire Services, Inc. ("Empire").
VMware Board Names Raghu Raghuram as CEO
58% of survey respondents consider human error their organization's biggest cyber vulnerability as hybrid workforce presents new challenges for cybersecurity teamsSUNNYVALE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Proofpoint, Inc. (NASDAQ: PFPT), a leading cybersecurity and compliance company, today released its inaugural 2021 Voice of the CISO report which explores key challenges facing chief information security officers (CISOs) after an unprecedented twelve months. Sixty-six percent of CISOs feel their organization is unprepared to handle a cyberattack and 58% consider human error to be their biggest cyber vulnerability, proving that the work-from-home model necessitated by the pandemic has tested CISOs like never before. This year’s Voice of the CISO report examines global third-party survey responses from more than 1,400 CISOs at mid to large size organizations across different industries. Throughout the course of Q1 2021, one hundred CISOs were interviewed in each market across 14 countries: the U.S., Canada, the UK, France, Germany, Italy, Spain, Sweden, the Netherlands, UAE, Saudi Arabia (KSA), Australia, Japan, and Singapore. The survey explores three key areas: the threat risk and types of cyber-attacks CISOs combat daily, the levels of employee and organizational preparedness to face them, and the impact of supporting a hybrid workforce as businesses prepare to re-open their corporate offices. It also covers the challenges CISOs face in their roles, position amongst the C-suite, and business expectations of their teams. “Last year, cybersecurity teams around the world were challenged to enhance their security posture in this new and changing landscape, literally overnight. This required a balancing act between supporting remote work and avoiding business interruption, while securing those environments,” commented Lucia Milică, global resident CISO at Proofpoint. “With the future of work becoming increasingly flexible, this challenge now extends into next year and beyond. In addition to securing many more points of attack and educating users on long-term remote and hybrid work, CISOs must instill confidence among customers, internal stakeholders, and the market that such setups are workable indefinitely.” Proofpoint’s Voice of the CISO 2021 report highlights general trends as well as regional differences amongst the global CISO community. Key global findings include: CISOs are on high alert across a range of threats: faced with a relentless attack landscape, 64% of surveyed CISOs feel at risk of suffering a material cyberattack in the next 12 months. When asked about the types of attacks they expect to face, there was no clear answer, with diverse threats such as Business Email Compromise (34%), Cloud Account Compromise (O365 or G suite accounts being compromised, 33%), and insider threats (31%) topping the list. Despite dominating recent headlines, supply chain attacks came in fifth with 29% and ransomware seventh with 27%.Organizational cyber preparedness is still a major concern: more than a year on into a pandemic that forever changed the threat landscape, 66% of CISOs feel their organization is unprepared to cope with a targeted cyberattack in 2021. Cyber risk is also on the rise: 53% of CISOs are more concerned about the repercussions of a cyberattack in 2021 than they were in 2020.User awareness doesn’t always lead to behavioral change: while more than half of survey respondents believe employees understand their role in protecting their organization from cyber threats, 58% of global CISOs still consider human error to be their organization's biggest cyber vulnerability. Global CISOs listed purposefully leaking data (criminal insider attack) and clicking malicious links or downloading compromised files as the most likely ways employees put their business at risk.Long term hybrid work environments present a new challenge for CISOs: 58% of CISOs agree that remote working has made their organization more vulnerable to targeted cyberattacks, with three in five revealing they had seen an increase in targeted attacks in the last 12 months. High risk, high reward likely to be a common cyber theme over the next two years: 63% of CISOs believe that cybercrime will become even more profitable for attackers, while 60% believe that it will become riskier for cybercriminals. CISOs will adapt their cybersecurity strategy to stay ahead: Overall, the majority of global CISOs expect their cybersecurity budget to increase by 11% or more over the next two years, and two in three (65%) believe they will be able to better resist and recover from cyberattacks by 2023. Top three priorities across the board for global CISOs over the next two years are: enhancing core security controls (35%), supporting remote working (33%), as well as security awareness (32%) and security automation (32%). 2020 elevated the CISO role, as well as the expectations from the business: 57% of global CISOs agree that expectations on their function are excessive. The perceived lack of support from the boardroom persists with only 25% of global CISOs strongly agreeing that their board see eye-to-eye with them on issues of cybersecurity. “The ‘good enough’ approach of the past 12 months will simply not work in the long term: with businesses unlikely to ever return to pre-pandemic working practices, the mandate to strengthen cyber security defenses has never been more pressing,” said Ryan Kalember, executive vice president of Cybersecurity Strategy for Proofpoint. “CISOs hold a business-critical function, now more than ever. The findings from our report emphasize that CISOs need the tools to mitigate risk and develop a strategy that takes a people-centric approach to cybersecurity protection to address ever-changing conditions, like those experienced by organizations throughout the pandemic.” To download the 2021 Voice of the CISO report, please visit:https://www.proofpoint.com/us/resources/white-papers/voice-of-the-ciso-report. For more information on Proofpoint’s unique approach to people-centric cybersecurity and compliance, please visit: https://www.proofpoint.com/us/why-proofpoint. About Proofpoint, Inc. Proofpoint, Inc. (NASDAQ: PFPT) is a leading cybersecurity and compliance company that protects organizations’ greatest assets and biggest risks: their people. With an integrated suite of cloud-based solutions, Proofpoint helps companies around the world stop targeted threats, safeguard their data, and make their users more resilient against cyber attacks. Leading organizations of all sizes, including more than half of the Fortune 1000, rely on Proofpoint for people-centric security and compliance solutions that mitigate their most critical risks across email, the cloud, social media, and the web. More information is available at www.proofpoint.com. Connect with Proofpoint: Twitter | LinkedIn | Facebook | YouTube Proofpoint is a registered trademark or tradename of Proofpoint, Inc. in the U.S. and/or other countries. All other trademarks contained herein are the property of their respective owners. PROOFPOINT MEDIA CONTACT:Kristy CampbellProofpoint, Inc.(408) firstname.lastname@example.org
Live video webcast with Outlook Therapeutics’ management team and key opinion leaders on Thursday, May 20th from 11:00 AM – 1:00 PM ETISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will host a Virtual Clinical Day for analysts and accredited institutional investors with live video webcast (details below) on Thursday, May 20, 2021 from 11:00 AM – 1:00 PM ET. During the Virtual Clinical Day, Outlook Therapeutics will provide an overview of its lead program, ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), its ongoing Phase 3 study in wet AMD, NORSE TWO, and its plans for a potential commercial rollout. Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics will host the event and will be joined by Outlook Therapeutics’ management team members, Terry Dagnon, Chief Operating Officer, and Jeff Evanson, Chief Commercial Officer. Key opinion leaders will also join the management team to discuss Outlook Therapeutics’ current clinical program and strategy, as well as the market need for a responsibly priced, ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration (FDA): Mark Humayun, MD, PhD, Medical Advisor to Outlook Therapeutics; Ophthalmologist, Engineer, Inventor; National Medal of Technology and Innovation awarded by President Barack Obama, 2016; Top 1% Ophthalmologists (U.S. News & World Report); Member, U.S. National Academics of Medicine and Engineering; Pyron Award, American Society of Retina Specialists; Past President, American Society of Retina Specialists; Co-inventor of Argus II, which offers functional sight to patients with complete retinal blindnessFiras M. Rahhal, MD, Senior Partner, Retina-Vitreous Associates Medical Group in Los Angeles and Associate Clinical Professor of Ophthalmology at the UCLA Geffen School of Medicine Webcast Details Interested participants and investors may dial into the event using (877) 407-9708 (domestic) or (201) 689-8259 (international), or can access the live video webcast and accompanying slide presentation on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com. The webcast replay will be archived for 90 days following the event. About ONS-5010 / LYTENAVA™ (bevacizumab-vikg) ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no currently approved ophthalmic formulations of bevacizumab are available, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacists, products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010 will reduce the need for use of unapproved repackaged IV bevacizumab from compounding pharmacists for retinal disease. ONS-5010 is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb) that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. With wet AMD, abnormally high levels of VEGF are secreted in the eye and lead to loss of vision. Anti-VEGF injection therapy blocks this growth. Since the advent of anti-VEGF therapy, it has become the standard-of-care treatment option within the retina community globally. About Outlook Therapeutics, Inc. Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, diabetic macular edema and branch retinal vein occlusion. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit www.outlooktherapeutics.com. CONTACTS: Media Inquiries:Harriet UllmanAssistant Vice PresidentLaVoieHealthScienceT: email@example.com Investor Inquiries: Jenene ThomasChief Executive OfficerJTC Team, LLCT: 833.475.8247OTLK@jtcir.com